Trial
NCT07006805
RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Cabaletta Bio
Collaborators
—
Condition
Relapsing Multiple Sclerosis (RMS)
Intervention
CABA-201
Why stopped
The study was withdrawn prior to site activation and before enrollment of any participants due to sponsor decision to reprioritize the development portfolio.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-25